$NMRA News
Last published 2mo ago
- 2mo agoNMRANeumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireFavorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in
- 3mo agoNMRANeumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026GlobeNewswireWATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms
- 4mo agoNMRANeumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline UpdateGlobeNewswireNavacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease agitation, NMRA-898
- 5mo agoNMRAANNUAL MEETING OF STOCKHOLDERS - NEUMORA THERAPEUTICS INCEarnings Call TranscriptsGood afternoon everyone. It is my pleasure to welcome you to the Numora Therapeutics 2026 Annual Meeting of Stockholders. I am Paul Burns, Chairman and Chief Executive Officer. As previously announced, we are holding our
- 6mo agoNMRANeumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms
- 6mo agoNMRANeumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireKOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and NMRA-898 in
- 6mo agoNMRANeumora NMRA-511 Update Conference Call - NEUMORA THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's eve
- 7mo agoNMRANeumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms
- 7mo agoNMRANeumora Fourth Quarter 2025 Earnings Conference Call - NEUMORA THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. Please be advised that today's confe
- 7mo agoNMRANeumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireNew data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for
- 8mo agoNMRANeumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026GlobeNewswireWATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms
- 9mo agoNMRANeumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireWATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms
- 10mo agoNMRANeumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming MilestonesGlobeNewswireMultiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215
- 10mo agoNMRANeumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease AgitationGlobeNewswireNMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with
- 1y agoNMRANeumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireAnnounced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of
- 1y agoNMRANeumora Therapeutics to Participate in Upcoming Conferences in NovemberGlobeNewswireWATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel
- 1y agoNMRANeumora Therapeutics R&D Day - NEUMORA THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's con
- 1y agoNMRANeumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898GlobeNewswireNMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in
- 1y agoNMRANeumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity ModelGlobeNewswireNMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading
- 1y agoNMRANeumora Therapeutics to Host Virtual R&D Day on October 27GlobeNewswireWATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel
- 1y agoNMRANeumora Therapeutics to Participate in Upcoming Conferences in SeptemberGlobeNewswireWATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel
- 1y agoNMRANeumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoNMRANeumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireInitiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of
- 1y agoNMRANeumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025GlobeNewswireWATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including
- 1y agoNMRAKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ:NMRA) breached their
- 1y agoNMRAKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ:...
- 1y agoNMRANeumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireOn track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder
- 1y agoNMRANeumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025GlobeNewswireWATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs
- 1y agoGLPGNMRAGalapagos Announces Executive Leadership UpdatesGlobeNewswireMr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the
- 1y agoNMRAShareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRAGlobeNewswireNEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ:NMRA). Shareholders who purchased shares of NMRA during the class
- 1y agoNMRAShareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of...
- 1y agoNMRAThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of...
- 1y agoNMRANeumora Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of...
- 1y agoNMRAINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Neumora To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoNMRASHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Neumora Therapeutics, Inc. ("Neumora" or the...
- 1y agoNMRASHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Neumora To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoNMRAThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRAGlobeNewswireNEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ:NMRA). Shareholders who purchased shares of NMRA during the class
- 1y agoNMRANeumora Therapeutics to Present at Leerink Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain
- 1y agoNMRAShareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRAGlobeNewswireNEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ:NMRA). Shareholders who purchased shares of NMRA during the class
- 1y agoNMRANeumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireKOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in
- 1y agoNMRANeumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NMRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of...
- 1y agoNMRAInvestors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of...
- 1y agoNMRAInvestors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRAGlobeNewswireNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ:NMRA). Shareholders who purchased shares of NMRA during the class period
- 1y agoNMRANeumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of...
- 1y agoNMRASHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Neumora To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoNMRANeumora Therapeutics Announces Leadership TransitionGlobeNewswirePaul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating
- 1y agoNMRANeumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive DisorderGlobeNewswireStudy did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in
- 1y agoNMRANeumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoNMRANeumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in
- 2y agoNMRANeumora Therapeutics to Participate in Upcoming Conferences in NovemberGlobeNewswireWATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain